With your own knowledge and the help of the following document:

Document 1 (Title: Toxin-Mediated Bacterial Diseases and Immunoprophylaxis): Diphtheria, caused by toxigenic strains of Corynebacterium diphtheriae, represents a paradigmatic toxin-mediated bacterial disease with distinctive pathophysiological mechanisms and immunological considerations. While relatively uncommon in developed nations due to widespread immunization, the disease remains endemic in regions with suboptimal vaccination coverage, presenting substantial morbidity and mortality, particularly in pediatric populations. The pathogenesis centrally involves exotoxin production by C. diphtheriae strains lysogenized with a bacteriophage carrying the tox gene. The diphtheria toxin, a single polypeptide comprising two functional domains, initially binds to cell surface receptors via its B-fragment, facilitating entry of the catalytic A-fragment into the cytoplasm. The A-fragment catalyzes ADP-ribosylation of elongation factor 2, irreversibly inhibiting protein synthesis and inducing cellular apoptosis. Local infection typically manifests as a distinctive gray-white pseudomembranous pharyngitis with regional lymphadenopathy, while toxin-mediated systemic complications include myocarditis and peripheral neuropathy, which account for the majority of fatalities. Immunization against diphtheria utilizes formaldehyde-treated toxin (toxoid) to induce neutralizing antibodies directed against the B-fragment, preventing cellular binding and internalization. This humoral immunity, mediated by circulating IgG antibodies, provides effective protection against toxin-mediated manifestations but does not prevent colonization by toxigenic strains. Protective efficacy correlates directly with antitoxin antibody titers, with levels exceeding 0.01 IU/mL considered protective. The conventional immunization schedule includes primary series administration during infancy followed by periodic boosters to maintain protective antibody levels throughout life. In contrast to cellular immunity (mediated by CD4+ T lymphocytes) or mucosal protection (mediated by secretory IgA), which play predominant roles in defense against intracellular pathogens and mucosal colonizers respectively, protection against diphtheria principally relies on circulating neutralizing antibodies interfering with toxin-receptor interaction. Unimmunized or inadequately immunized individuals remain susceptible to both localized disease and potentially lethal systemic complications through toxin dissemination.
Document 2 (Title: Infectious Mononucleosis and Other Manifestations of Epstein Barr Virus Infection): Infectious mononucleosis is a syndrome characterized by fever, pharyngitis/tonsillitis, lymphadenopathy, and peripheral atypical lymphocytosis. Etiologic agents: Ninety percent of cases of typical mononucleosis are caused by the Epstein Barr virus (EBV) from the Herpesviridae family. The virus first infects oropharyngeal epithelial cells and B cells. Some of these B cells are transformed into immortal plasma cells and are triggered to produce polyclonal gamma globulins, which are detected as nonspecific heterophile antibodies. The activated B cells, which are visualized as atypical lymphocytes, stimulate proliferation of T cells, leading to the enlargement of the lymph nodes, tonsils, spleen, and liver. After the primary infection, EBV remains latent in B cells and oral epithelial cells; its reactivation may lead to uncontrolled monoclonal lymphoproliferation. The shedding of active EBV virus takes place intermittently thereafter from the asymptomatic host. Other pathogens causing similar syndromes include cytomegalovirus (CMV), accounting for 7% of cases, as well as human herpesvirus 6 (HHV 6), human herpesvirus 7 (HHV 7), HIV, and Toxoplasma gondii. Reservoir and transmission: Humans are the only reservoir for EBV. The pathogen is ubiquitous worldwide; almost all adults become seropositive at some point. EBV is spread via direct contact, usually through saliva; transmission is also possible by blood transfusion, bone marrow, and solid organ transplant. Incubation period: The incubation period for EBV infection is 30 to 50 days.
Document 3 (Title: Antiviral Strategies Against Orthomyxoviruses): Influenza viruses, belonging to the Orthomyxoviridae family, cause substantial seasonal morbidity and mortality worldwide, with periodic pandemic potential through antigenic shift events. These enveloped, negative-sense, segmented RNA viruses demonstrate a complex replication cycle offering multiple potential targets for therapeutic intervention. The viral surface presents two major glycoproteins: hemagglutinin (HA), mediating host cell attachment and membrane fusion, and neuraminidase (NA), facilitating viral release and spread. Current antiviral strategies target distinct phases of the viral replication cycle, with neuraminidase inhibitors representing the predominant class of clinically approved agents. Viral neuraminidase functions as a sialidase, cleaving sialic acid residues from both viral and cellular glycoproteins. This enzymatic activity proves essential during the viral release phase, preventing virion aggregation and facilitating dissemination to adjacent cells. Without functional neuraminidase, newly formed virions remain tethered to the infected cell surface and to each other, substantially limiting viral spread. Neuraminidase inhibitors, including oseltamivir (oral), zanamivir (inhaled), and peramivir (intravenous), are structural analogs of sialic acid that competitively bind the enzyme's active site with high specificity and affinity. These agents demonstrate activity against both influenza A and B viruses, though effectiveness varies with viral strain and timing of administration. Clinical efficacy is maximized when treatment begins within 48 hours of symptom onset, reducing symptom duration by approximately 24-36 hours and potentially decreasing complication rates. Alternative antiviral approaches include M2 ion channel inhibitors (amantadine, rimantadine), which block viral uncoating but demonstrate limited utility due to widespread resistance and ineffectiveness against influenza B. More recently developed agents target viral RNA-dependent RNA polymerase, including baloxavir marboxil, which inhibits cap-dependent endonuclease activity essential for viral transcription initiation. Unlike direct-acting antivirals targeting viral proteases or host-encoded proteases essential for viral protein processing, neuraminidase inhibitors do not interfere with proteolytic events but rather disrupt the final phase of the viral replication cycle, offering a distinct mechanistic approach to influenza management.

Answer the following multiple-choice question.
Question: A 6-year-old male who recently immigrated to the United States from Asia is admitted to the hospital with dyspnea. Physical exam reveals a gray pseudomembrane in the patient's oropharynx along with lymphadenopathy. The patient develops myocarditis and expires on hospital day 5. Which of the following would have prevented this patient's presentation and decline?
Options:
A. Increased CD4+ T cell count
B. Secretory IgA against viral proteins
C. Increased IgM preventing bacterial invasion
D. Circulating IgG against AB exotoxin

Respond strictly in valid JSON format as follows:
{"answer_choice": "A"} ‚Üê if A is the answer
Output only the JSON object. Do not include any explanation, commentary, markdown, or extra text.